Evidence map›Paper›PMID 27163679›Full record

ReviewJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2016

Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain.

John L Hamilton, Masashi Nagao, Brett R Levine, Di Chen, Bjorn R Olsen, Hee-Jeong Im

Open access · greenAbstract readReview
In one paragraph

Review in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 149 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
149citing papers in PubMed, 1 pooled it
15.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

149 citing papers in PubMed, 1 synthesis or guideline pooled it, 283 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

89 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

John L HamiltonDepartment of Biochemistry, Rush University Medical Center, Chicago, IL, USA.
Masashi NagaoDepartment of Developmental Biology, Harvard School of Dental Medicine, Boston, MA, USA.
Brett R LevineDepartment of Orthopedic Surgery, Rush University Medical Center, Chicago, IL, USA.
Di ChenDepartment of Biochemistry, Rush University Medical Center, Chicago, IL, USA.
Bjorn R OlsenDepartment of Developmental Biology, Harvard School of Dental Medicine, Boston, MA, USA.
Hee-Jeong ImDepartment of Biochemistry, Rush University Medical Center, Chicago, IL, USA.
Rush University Medical Center · USHarvard University · US

Funding

STRUCTURE OF TYPE I AND TYPE II PROCOLLAGENSR01AR036819 · NIAMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI OLSEN, BJORN REINO · 1986 to 2016
$8.7M
Pain Mechanisms of Knee Joint OsteoarthritisR01AR062136 · NIAMS · RUSH UNIVERSITY MEDICAL CENTER · PI CHEN, DI · 2012 to 2016
$1.7M
Allosteric Small Molecule Inhibitor Of Nerve Growth Factor Signaling in Low Back PainR21AR067935 · NIAMS · RUSH UNIVERSITY MEDICAL CENTER · PI CHEN, DI · 2015 to 2016
$375k
Anti-VEGF Therapy in Osteoarthritis and Associated PainF31AR070002 · NIAMS · RUSH UNIVERSITY MEDICAL CENTER · PI HAMILTON, JOHN L · 2016 to 2017
$84k
OSTEOARTHRITIS AND KNEE JOINT PAINI01BX002647 · VA · JESSE BROWN VA MEDICAL CENTER · PI SAMPEN, HEE-JEONG IM · 2015 to 2023
–
BLRD VA I01 BX002647NIAMS NIH HHS F31 AR070002NIAMS NIH HHS R01 AR036819NIAMS NIH HHS R01 AR062136NIAMS NIH HHS R21 AR067935
6 · The paper itself

Abstract

Increased vascular endothelial growth factor (VEGF) levels are associated with osteoarthritis (OA) progression. Indeed, VEGF appears to be involved in OA-specific pathologies including cartilage degeneration, osteophyte formation, subchondral bone cysts and sclerosis, synovitis, and pain. Moreover, a wide range of studies suggest that inhibition of VEGF signaling reduces OA progression. This review highlights both the potential significance of VEGF in OA pathology and pain, as well as potential benefits of inhibition of VEGF and its receptors as an OA treatment. With the emergence of the clinical use of anti-VEGF therapy outside of OA, both as high-dose systemic treatments and low-dose local treatments, these particular therapies are now more widely understood. Currently, there is no established disease-modifying drug available for patients with OA, which warrants continued study of the inhibition of VEGF signaling in OA, as stand-alone or adjuvant therapy. © 2016 American Society for Bone and Mineral Research.

Indexed as

Signal TransductionFemaleHumansMaleOsteoarthritisPainVascular Endothelial Growth Factor AVascular Endothelial Growth Factor AVEGFA protein, humanANGIOGENESISOSTEOARTHRITISVASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR (VEGFR)VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF)

Identifiers

PMID27163679
PMCPMC4863467
OpenAlexW2295088026

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.